The effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambs

Basit Öğe Kaydı
dc.contributor.authorAltan, Feray
dc.contributor.authorİpek, Duygu Neval Sayın
dc.contributor.authorÇorum, Orhan
dc.contributor.authorAlp, Simten Yeşilmen
dc.contributor.authorİpek, Polat
dc.contributor.authorÜney, Kamil
dc.date.accessioned2020-03-26T20:19:27Z
dc.date.available2020-03-26T20:19:27Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Veteriner Fakültesi, Klinik Öncesi Bilimler Bölümüen_US
dc.description.abstractThe study aimed to define the effects of M. haemolytica and a single oral dose of albendazole on the single-dose pharmacokinetics of marbofloxacin in lambs. The pharmacokinetic-pharmacodynamic integration of marbofloxacin was applied to describe a 3 mg/kg intramuscular dose in lambs. The 6 healthy and 12 naturally infected with M. haemolytica lambs (Akkaraman, males weighing 10-15 kg and aged 2-3 months) were used in this study. In the marbofloxacin group, 6 healthy lambs received marbofloxacin. In the albendazole group after 2 weeks washout period, the same animals received marbofloxacin on 1 h after albendazole. In the diseased marbofloxacin group, 6 lambs naturally infected with M. haemolytica received marbofloxacin. In the diseased albendazole group, 6 lambs naturally infected with M. haemolytica received marbofloxacin on 1 h after albendazole. The marbofloxacin and albendazole were administered each as a single dose of 3 mg/kg intramuscular and 7.5 mg/kg oral, respectively, in the respective groups. Plasma concentration of marbofloxacin was measured with HPLC-UV and pharmacokinetic parameters were analyzed by non-compartmental model. Albendazole did not change the pharmacokinetic profiles of marbofloxacin in healthy and diseased lambs. However, M. haemolytica affected the pharmacokinetics of marbofloxacin in diseased lambs, AUC(0-24)/MIC90 ratio was not found to be higher than 125, but C-max/MIC90 ratios was found to be higher than 10 for an MIC value of 0.25 mu g/mL in all groups. The marbofloxacin dose described in this study may not be effective for the treatment of infections due to M. haemolytica in lambs, with MIC <= 0.25 mu g/mL.en_US
dc.identifier.citationAltan, F., Ipek, D.N.S., Corum, O., Alp,S.Y., Ipek, P., Uney, K.(2019). The Effects of Mannheimia Haemolytica and Albendazole on Marbofloxacin Pharmacokinetics in Lambs. Tropıcal Anımal Health And Productıon, 51,(8), 2603-2610.
dc.identifier.doi10.1007/s11250-019-01980-5en_US
dc.identifier.endpage2610en_US
dc.identifier.issn0049-4747en_US
dc.identifier.issn1573-7438en_US
dc.identifier.issue8en_US
dc.identifier.pmid31230255en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2603en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s11250-019-01980-5
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38274
dc.identifier.volume51en_US
dc.identifier.wosWOS:000494799400057en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUney, Kamil
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofTROPICAL ANIMAL HEALTH AND PRODUCTIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAlbendazoleen_US
dc.subjectLamben_US
dc.subjectMannheimia haemolyticaen_US
dc.subjectMarbofloxacinen_US
dc.subjectPharmacokineticsen_US
dc.titleThe effects of Mannheimia haemolytica and albendazole on marbofloxacin pharmacokinetics in lambsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
KAMİL ÜNEY.pdf
Boyut:
297.72 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Klinik Öncesi Bilimler/Makale Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu